

# Miklos Egyed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5035420/publications.pdf>

Version: 2024-02-01

15  
papers

903  
citations

933447

10  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

920  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1278-1291.	13.7	393
2	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. <i>Lancet Haematology, the</i> , 2017, 4, e225-e236.	4.6	224
3	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	7.2	72
4	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. <i>Blood Advances</i> , 2020, 4, 5825-5835.	5.2	60
5	ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 31-31.	1.4	47
6	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. <i>Future Oncology</i> , 2021, 17, 1449-1458.	2.4	31
7	Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7539-7539.	1.6	17
8	MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7002-7002.	1.6	17
9	Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. <i>European Journal of Haematology</i> , 2017, 98, 106-111.	2.2	12
10	Recommendations for the diagnosis and treatment of patients with polycythaemia vera. <i>European Journal of Haematology</i> , 2018, 101, 654-664.	2.2	11
11	Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia. <i>Cardiovascular Toxicology</i> , 2021, 21, 236-247.	2.7	4
12	Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].. <i>Journal of Clinical Oncology</i> , 2022, 40, 7061-7061.	1.6	3
13	Is iron deficiency anemia always microcytic?. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 199-201.	0.4	1
14	Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. <i>Future Oncology</i> , 2022, 18, 755-769.	2.4	1
15	Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin. <i>European Journal of Haematology</i> , 2020, 105, 408-418.	2.2	0